- Apr 29, 2022
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
- Apr 29, 2022
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor
- Apr 29, 2022
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor
- Apr 28, 2022
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
- Apr 25, 2022
NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma
- Apr 25, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
- Apr 20, 2022
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)
- Apr 19, 2022
NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT
- Apr 19, 2022
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
- Apr 18, 2022
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
- Apr 13, 2022
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
- Apr 12, 2022
How to Prevent Neutropenic Sepsis on Treatment? Know Your ANC (Absolute Neutrophil Count)
- Apr 10, 2022
MPE survey on myeloma and AL amyloidosis diagnosis
- Apr 6, 2022
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
- Apr 3, 2022
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
- Apr 3, 2022
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
- Mar 31, 2022
IMF - International Myeloma Foundation: Patient Handbook 2022